cisplatin

Documents about cisplatin

• Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment#917223ClinicalTrials.gov
• Effects of DPP4 Inhibitor on Cisplatin Induced Acute Kidney Injury#873282ClinicalTrials.gov
• Cisplatin Disposition and Kidney Injury#897957ClinicalTrials.gov
• NAC to Prevent Cisplatin-induced Hearing Loss#856438ClinicalTrials.gov
• Docetaxal & Cisplatin vs LDFRT + Docetaxal & Cisplatin in Locally Advanced NPC#829183ClinicalTrials.gov
• Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer#874631ClinicalTrials.gov
• Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma#910946ClinicalTrials.gov
• Guidance on the short hydration method for cisplatin administration#1001660OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Sub-nephrotoxic cisplatin sensitizes rats to acute renal failure and increases urinary excretion of fumarylacetoacetase#337358Gestión del Repositorio Documental de la Universidad de Salamanca
• Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer#966460ClinicalTrials.gov
• Comparison of Rapamycin and 3-Methyladenine in Cisplatin-Induced Experimental Cardiotoxicity#256621İzmir Yüksek Teknoloji Enstitüsü
• Evaluation of the Effect of Acetazolamide, Mannitol and N-acetylcysteine on Cisplatin-Induced Nephrotoxicity#806245ClinicalTrials.gov
• Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer#834811ClinicalTrials.gov
• Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss#894993ClinicalTrials.gov
• Pemetrexed/Cisplatin Versus Gemcitabine/Cisplatin According to Thymidylate Synthase Expression#884969ClinicalTrials.gov
• Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.#859613ClinicalTrials.gov
• Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement#886361ClinicalTrials.gov
• Cisplatin Desensitization in a Patient with Nasopharyngeal Carcinoma Experiencing Urticarial Allergic to Cisplatin#930415Acta Interna: The Journal of Internal Medicine
• Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer#847303ClinicalTrials.gov
• Efficacy Study for Postoperative Chemoradiation Using Triweekly Cisplatin in Cervical Cancer Patients#857078ClinicalTrials.gov
• Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer#884947ClinicalTrials.gov
• Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer#899386ClinicalTrials.gov
• Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions#870019ClinicalTrials.gov
• Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer#897498ClinicalTrials.gov
• Genotype-drive Study of Irinotecan-Cisplatin Combination for Advanced Gastric Cancer#917118ClinicalTrials.gov
• Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate#870582ClinicalTrials.gov
• Evaluation of the Effect of Genetic Polymorphisms in ERCC1 and OCT2 on the Occurrence and Severity of Cisplatin-induced Nephrotoxicity#907821ClinicalTrials.gov
• Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)#444883ClinicalTrials.gov
• Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer#839837ClinicalTrials.gov
• Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients#856270ClinicalTrials.gov
• Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer#202509HAL (France)
• Mitophagy in cisplatin-induced kidney injury: regulatory mechanisms and therapeutic targets#253490Europe PMC
• Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal Carcinoma#810814ClinicalTrials.gov
• Gabapentin in the Prevention of Nausea and Vomiting Induced by Chemotherapy#855824ClinicalTrials.gov
• Intra-arterial Versus Intravenous Cisplatin, Combined With Radiation, for Oral Cavity and Oropharynx Cancer#856779ClinicalTrials.gov
• Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction Cancer#887304ClinicalTrials.gov
• Pharmacogenomic Study of Docetaxel and Cisplatin, Followed by Docetaxel, Cisplatin and Irradiation.#892624ClinicalTrials.gov
• Cisplatin-induced Cochlear and Vestibular Damage in Head and Neck Cancer#805001ClinicalTrials.gov
• Investigation of Cisplatin-Related Kidney Toxicity#804862ClinicalTrials.gov
• Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma#861740ClinicalTrials.gov
• Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer#874880ClinicalTrials.gov
• Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors#898412ClinicalTrials.gov
• Gemcitabine/Vinorelbine Versus Gemcitabine/Cisplatin Versus Gemcitabine/Capecitabine in Metastatic Breast Cancer#902069ClinicalTrials.gov
• Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy#905491ClinicalTrials.gov
• Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients#966442ClinicalTrials.gov
• Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid Cancer#968486ClinicalTrials.gov
• Application and mechanistic research of novel therapeutic strategies in cisplatin-resistant small cell lung cancer#4521Europe PMC
• Local application of otoprotective compounds other than sodium thiosulfate to prevent cisplatin-induced hearing loss: a systematic review.#151538PubMed
• Local application of otoprotective compounds other than sodium thiosulfate to prevent cisplatin-induced hearing loss: a systematic review#253521Europe PMC
• A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC#852947ClinicalTrials.gov